Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • Resource and Technical Advances
    • Clinical Medicine
    • Reviews
    • Editorials
    • Perspectives
    • Top read articles
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
CD47 antibody blockade suppresses microglia-dependent phagocytosis and monocyte transition to macrophages, impairing recovery in EAE
Huan Wang, … , Sridaran Natesan, Francis W. Luscinskas
Huan Wang, … , Sridaran Natesan, Francis W. Luscinskas
Published September 30, 2021
Citation Information: JCI Insight. 2021;6(21):e148719. https://doi.org/10.1172/jci.insight.148719.
View: Text | PDF
Research Article Inflammation

CD47 antibody blockade suppresses microglia-dependent phagocytosis and monocyte transition to macrophages, impairing recovery in EAE

  • Text
  • PDF
Abstract

Experimental autoimmune encephalomyelitis (EAE) is a well-characterized animal model of multiple sclerosis. During the early phase of EAE, infiltrating monocytes and monocyte-derived macrophages contribute to T cell recruitment, especially CD4+ T cells, into the CNS, resulting in neuronal demyelination; however, in later stages, they promote remyelination and recovery by removal of myelin debris by phagocytosis. Signal regulatory protein α and CD47 are abundantly expressed in the CNS, and deletion of either molecule is protective in myelin oligodendrocyte glycoprotein–induced EAE because of failed effector T cell expansion and trafficking. Here we report that treatment with the function blocking CD47 Ab Miap410 substantially reduced the infiltration of pathogenic immune cells but impaired recovery from paresis. The underlying mechanism was by blocking the emergence of CD11chiMHCIIhi microglia at peak disease that expressed receptors for phagocytosis, scavenging, and lipid catabolism, which mediated clearance of myelin debris and the transition of monocytes to macrophages in the CNS. In the recovery phase of EAE, Miap410 Ab–treated mice had worsening paresis with sustained inflammation and limited remyelination as compared with control Ab–treated mice. In summary, Ab blockade of CD47 impaired resolution of CNS inflammation, thus worsening EAE.

Authors

Huan Wang, Gail Newton, Liguo Wu, Lih-Ling Lin, Amy S. Miracco, Sridaran Natesan, Francis W. Luscinskas

×

Figure 4

CD47 Ab dramatically reduces CD45loCD11chiMHCIIhi microglial cells in SCs at peak disease.

Options: View larger image (or click on image) Download as PowerPoint
CD47 Ab dramatically reduces CD45loCD11chiMHCIIhi microglial cells in SC...
(A) Representative plots of CD45lo cells in SCs and gating on CD11chiMHCIIhi microglia at peak disease in Ab-treated and nonimmunized control (Ctr) mice. (B–D) Representative plot of CD11chiMHCIIhi (B) and their percentage (C) and total number (D) within the CD45lo cell population. n = 6–7 mice per group. (E and F) Representative plots (E) and normalized surface expression of antigens (F) on CD45lo cells from SCs of Ctr, MOPC-21, and Miap410 Ab–treated mice. n = 3 mice per group. (G) Representative images of Luxol fast blue and Tmem119 antigen staining in SCs of EAE mice. Scale bars represent 200 μm in SCs and 100 μm for zoomed-in images. Images are representative of n = 3 mice per group. All data from SCs. Data are shown as mean ± SEM values. *P < 0.05, **P < 0.01, ***P < 0.001. One-way ANOVA with Tukey’s post hoc test was used for the statistical significance.

Copyright © 2023 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts